North Penn projects 14.6% rise in benefits costs; GLP‑1 weight‑loss drugs drive much of pharmacy increase

District administration told the finance committee on March 3 that the North Penn School District’s benefit renewal projects a combined increase of about 14.6 percent for the coming year, with the district’s portion of the consortium renewal estimated at roughly $43 million.

Miss Houser presented preliminary CPaaS consortium results showing per‑employee per‑month averages near $21.20. She said the renewal across the 17 consortium members rose from an early projection of about $206 million to a final estimate near $235 million, with North Penn’s share estimated at approximately $43 million.

Prescription spending is a key driver: the pharmacy component for the district rose roughly 17 percent year over year, moving from about $8.0 million to a projected $9.4 million. Administration identified GLP‑1 weight‑loss medications (transcript referenced brand names) as a large contributor: roughly 135 people generated about $2.4 million in GLP‑1 claims in the most recent claims year. Miss Houser said excluding GLP‑1 medications from the formulary would materially reduce next year’s medical and Rx cost increases (her slide showed medical would drop about 12.5 percent and Rx about 8.9 percent in that hypothetical), but she warned of tradeoffs and contractual constraints tied to pharmacy rebates and program integrity.

The administration said it is discussing options with union leadership and benefit managers, including formulary design, co‑payments or targeted incentives, and that crafting a fair approach will likely take time. Miss Houser disclosed she is enrolled in one of the GLP‑1 programs; she emphasized administration will seek creative solutions but may also provide a runway (up to 12 months) before making coverage changes.

Board members asked for more trend analysis and comparative benchmarks; they requested Willis Towers (the benefits consultant) provide trend context and comparison to its broader book of business. The administration said it will present more detailed benefits analytics and alternative scenarios at a future meeting.